Quantbot Technologies LP Has $508,000 Stock Holdings in AVANOS MEDICAL, INC. $AVNS

Key Points

• Quantbot Technologies LP increased its stake in Avanos Medical by 782.1%, owning 35,442 shares valued at about $508,000 following the purchase of 31,424 additional shares in Q1.
• Avanos Medical's stock was rated a "hold" by Zacks Research, with its average rating currently at "hold," following a downgrade from a "strong-buy" to a "buy" by Wall Street Zen.
• In a recent earnings report, Avanos Medical missed the consensus EPS estimate of $0.18, reporting $0.17, and set FY 2025 guidance at 0.750-0.950 EPS.

Quantbot Technologies LP boosted its holdings in shares of AVANOS MEDICAL, INC. (NYSE:AVNS - Free Report) by 782.1% in the first quarter, according to its most recent filing with the SEC. The firm owned 35,442 shares of the company's stock after acquiring an additional 31,424 shares during the period. Quantbot Technologies LP owned 0.08% of AVANOS MEDICAL worth $508,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in AVNS. Brown Advisory Inc. grew its holdings in AVANOS MEDICAL by 1.4% during the first quarter. Brown Advisory Inc. now owns 1,931,163 shares of the company's stock valued at $27,674,000 after purchasing an additional 26,069 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of AVANOS MEDICAL by 32.3% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 608,635 shares of the company's stock valued at $8,722,000 after buying an additional 148,619 shares during the period. Northern Trust Corp grew its stake in AVANOS MEDICAL by 4.9% in the fourth quarter. Northern Trust Corp now owns 526,763 shares of the company's stock valued at $8,386,000 after acquiring an additional 24,720 shares during the period. D. E. Shaw & Co. Inc. grew its stake in AVANOS MEDICAL by 43.1% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 494,627 shares of the company's stock valued at $7,874,000 after acquiring an additional 148,902 shares during the period. Finally, Clark Estates Inc. NY acquired a new position in AVANOS MEDICAL in the first quarter valued at about $7,077,000. 95.17% of the stock is owned by institutional investors and hedge funds.

Insider Activity at AVANOS MEDICAL

In related news, Director Gary Blackford acquired 40,000 shares of the business's stock in a transaction dated Wednesday, August 13th. The stock was bought at an average price of $10.99 per share, with a total value of $439,600.00. Following the acquisition, the director owned 40,000 shares in the company, valued at $439,600. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.64% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Wall Street Zen lowered AVANOS MEDICAL from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Zacks Research upgraded shares of AVANOS MEDICAL to a "hold" rating in a report on Tuesday, August 12th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has an average rating of "Hold".

AVANOS MEDICAL Stock Up 0.5%

Shares of AVANOS MEDICAL stock traded up $0.06 during trading hours on Friday, reaching $11.93. 647,282 shares of the company's stock were exchanged, compared to its average volume of 820,234. The company has a 50 day moving average of $11.62 and a two-hundred day moving average of $12.80. AVANOS MEDICAL, INC. has a fifty-two week low of $9.30 and a fifty-two week high of $25.36. The company has a current ratio of 2.64, a quick ratio of 1.58 and a debt-to-equity ratio of 0.12. The stock has a market cap of $553.74 million, a P/E ratio of -1.19 and a beta of 1.12.

AVANOS MEDICAL (NYSE:AVNS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). AVANOS MEDICAL had a negative net margin of 66.89% and a positive return on equity of 6.16%. The company had revenue of $175.00 million for the quarter, compared to analyst estimates of $165.50 million. During the same period last year, the company posted $0.34 earnings per share. AVANOS MEDICAL has set its FY 2025 guidance at 0.750-0.950 EPS. On average, sell-side analysts forecast that AVANOS MEDICAL, INC. will post 1.32 EPS for the current fiscal year.

About AVANOS MEDICAL

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.